 Connection
Samer Al Hadidi to Antibodies, Monoclonal
This is a "connection" page, showing publications Samer Al Hadidi has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.751 |
|
|
|
-
Al Hadidi S, Miller-Chism CN, Kamble R, Mims M. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e579-e589.
Score: 0.537
-
Rafae A, van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. Oncologist. 2024 Mar 04; 29(3):200-212.
Score: 0.175
-
Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280.
Score: 0.039
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|